New CRISPR screen maps what genes do inside tissue, revealing tumor and immune drivers

Tissues are organized in space. Where a cell sits, and which neighbors it touches, shapes its behavior in cancer, immunity, and aging. Spatial omics can map this organization, but it mostly describes tissues rather than testing which genes cause a given spatial pattern. Conventional CRISPR screens test gene function at scale, but they usually read out dissociated cells and lose location.

The authors developed spatial CRISPR screen sequencing (SPAC-seq), a high-throughput platform that connects gene perturbations to spatial phenotypes and signaling pathways. They paired it with TARDIS, a statistical toolkit for analyzing spatial perturbation data and prioritizing gene targets. The abstract does not describe the experimental systems, but the mouse-style gene names (Icam1, Cd44, Spp1) suggest murine models.

Three applications are highlighted. First, loss of Icam1 in tumor cells was linked to increased metastasis through immune suppression and macrophage polarization. Second, in CD8+ T cells, Cd44 regulated spatial phenotypes through interaction with Spp1 on macrophages. Third, the authors proposed a model in which a transcription factor-chemokine receptor axis couples cell state to chemotaxis.

If the approach generalizes, it could help researchers identify genes that control immune cell positioning, tumor-immune interactions, and tissue organization. Those processes matter in cancer, chronic inflammation, and immune aging. The authors present it as a framework usable across many biological and disease contexts.

Several caveats apply. Only the abstract was available, so sensitivity, throughput, resolution, reproducibility, and validation experiments cannot be assessed. The findings appear to be preclinical, and links between gene loss and metastasis or immune phenotypes need independent confirmation. The authors also report a patent application on SPAC-seq.